The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With <scp>MASLD</scp> Enrolled in <scp>TARGET</scp>‐<scp>NASH</scp>
Polypharmacy is common among patients with MASLD. Those with cirrhosis are most affected, and women with cirrhosis are at an even greater risk. Opioid, benzodiazepine, and nonsteroidal anti-inflammatory drug use is prevalent among patients with cirrhosis despite the known associated risks. Frequent medication use for chronic pain in patients with cirrhosis highlights the need for management plans that optimise safety balanced against therapeutic efficacy.
Authors
- Leen Al‐Sayyed
- Heather Morris (ORCID: https://orcid.org/0000-0002-7540-5315)
- Feng Yu (ORCID: https://orcid.org/0000-0002-7844-6534)
- A. Sidney Barritt (ORCID: https://orcid.org/0000-0002-4200-3256)
- Arun Jayant Sanyal (ORCID: https://orcid.org/0000-0001-8682-5748)
- Brent A. Neuschwander‐Tetri (ORCID: https://orcid.org/0000-0002-8520-7398)
- Andrea R. Mospan (ORCID: https://orcid.org/0000-0002-3419-8276)
- Michael Fried
- Breda Muñoz
- S. Abraham
Institutions
- University of North Carolina at Chapel Hill (US)
- Target (United States) (US)
- BJC HealthCare (US)
- Virginia Commonwealth University (US)
- Saint Louis University (US)
Publication Details
- Journal
- Alimentary Pharmacology & Therapeutics
- Published
- 2025-07-16
- DOI
- https://doi.org/10.1111/apt.70278
- Citations
- 3
- Primary Topic
- Pharmaceutical Practices and Patient Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.67